Related Experiment Video

Updated: May 4, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

2.8K

Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism

Ashfaque A Memon1, Jan Sundquist2, Bengt Zöller1

  • 1Center for Primary Health Care Research, Department of Clinical Sciences, Skåne University Hospital, Lund University, Sweden.

Thrombosis Research
|December 24, 2013
PubMed
Abstract

Insights

Lower levels of apolipoprotein M (ApoM) may predict recurrent venous thromboembolism (VTE) in men. ApoM protects against atherosclerosis, but its role in VTE recurrence differs by gender.

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Biochemistry

Background:

  • Apolipoprotein M (ApoM) is known to protect against atherosclerosis.
  • The role of ApoM in protecting against recurrent venous thromboembolism (VTE) is not well understood.

Purpose of the Study:

  • To investigate the association between plasma levels of ApoM and the risk of recurrent VTE.
  • To determine if ApoM levels differ between patients with and without recurrent VTE.
  • To explore potential gender-specific differences in the association between ApoM and VTE recurrence.

Main Methods:

  • Plasma ApoM levels were measured in patients from the Malmö Thrombophilia Study (MATS) with a history of VTE.
  • Patients were followed for recurrent VTE after anticoagulant treatment.
  • Apolipoprotein M (ApoM) levels were quantified using a sandwich ELISA method.

Main Results:

  • Overall, no significant difference in ApoM levels was observed between patients with recurrent and non-recurrent VTE.
  • Male patients with recurrent VTE had significantly lower ApoM levels compared to non-recurrent VTE patients.
  • Lower ApoM levels in male patients were associated with an increased risk of VTE recurrence, independent of inherited thrombophilia and BMI.

Conclusions:

  • Plasma ApoM levels may differ in recurrent VTE based on gender.
  • Lower ApoM levels are predictive of VTE recurrence in male patients.
  • ApoM's role in VTE recurrence appears to be gender-dependent.
Keywords:
Apolipoprotein MRecurrenceRisk factorsVenous thrombosis

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.4K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
39
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K